CYANOTECH CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CYANOTECH CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Mar 31, 2018 | $8.10M | Jun 21, 2018 |
| FY2018 | Dec 31, 2017 | $9.15M | Jun 21, 2018 |
| FY2018 | Sep 30, 2017 | $8.06M | Jun 21, 2018 |
| FY2018 | Jun 30, 2017 | $8.81M | Jun 21, 2018 |
| FY2018 | Mar 31, 2017 | $7.25M | Jun 21, 2018 |
| FY2018 | Dec 31, 2016 | $7.61M | Jun 21, 2018 |
| FY2018 | Sep 30, 2016 | $9.86M | Jun 21, 2018 |
| FY2018 | Jun 30, 2016 | $7.32M | Jun 21, 2018 |
| FY2018 | Mar 31, 2016 | $31.84M | Jun 21, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $24.22M | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | $23.07M | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | $23.18M | Jun 26, 2024 |
| FY2024 | Mar 31, 2022 | $35.97M | Jun 26, 2024 |
| FY2023 | Mar 31, 2021 | $32.35M | Jun 27, 2023 |
| FY2022 | Mar 31, 2020 | $31.90M | Jun 22, 2022 |
| FY2021 | Mar 31, 2019 | $30.20M | Jun 22, 2021 |
| FY2020 | Mar 31, 2018 | $34.12M | Jun 23, 2020 |
| FY2018 | Mar 31, 2017 | $32.04M | Jul 1, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Mar 31, 2017 | $7.25M | Jun 22, 2017 |
| FY2017 | Dec 31, 2016 | $7.61M | Jun 22, 2017 |
| FY2017 | Sep 30, 2016 | $9.86M | Jun 22, 2017 |
| FY2017 | Jun 30, 2016 | $7.32M | Jun 22, 2017 |
| FY2017 | Mar 31, 2016 | $8.20M | Jun 22, 2017 |
| FY2017 | Dec 31, 2015 | $7.53M | Jun 22, 2017 |
| FY2017 | Sep 30, 2015 | $8.52M | Jun 22, 2017 |
| FY2017 | Jun 30, 2015 | $7.59M | Jun 22, 2017 |
| FY2016 | Mar 31, 2015 | $8.55M | Jun 23, 2016 |
| FY2016 | Dec 31, 2014 | $9.69M | Jun 23, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $6.88M | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | $5.95M | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | $7.26M | Jun 26, 2024 |
| FY2024 | Mar 31, 2022 | $13.57M | Jun 26, 2024 |
| FY2021 | Mar 31, 2021 | $2.77M | Jun 22, 2021 |
| FY2021 | Dec 31, 2020 | $2.07M | Jun 22, 2021 |
| FY2021 | Sep 30, 2020 | $3.30M | Jun 22, 2021 |
| FY2021 | Jun 30, 2020 | $2.97M | Jun 22, 2021 |
| FY2021 | Mar 31, 2020 | $3.08M | Jun 22, 2021 |
| FY2021 | Dec 31, 2019 | $2.88M | Jun 22, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($3.20M) | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | ($5.27M) | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | ($3.44M) | Jun 26, 2024 |
| FY2024 | Mar 31, 2022 | $2.15M | Jun 26, 2024 |
| FY2021 | Mar 31, 2021 | ($200.0K) | Jun 22, 2021 |
| FY2021 | Dec 31, 2020 | $827.0K | Jun 22, 2021 |
| FY2021 | Sep 30, 2020 | $155.0K | Jun 22, 2021 |
| FY2021 | Jun 30, 2020 | $138.0K | Jun 22, 2021 |
| FY2021 | Mar 31, 2020 | $121.0K | Jun 22, 2021 |
| FY2021 | Dec 31, 2019 | $171.0K | Jun 22, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($2.51M) | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | ($4.59M) | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | ($2.92M) | Jun 26, 2024 |
| FY2024 | Mar 31, 2022 | $2.57M | Jun 26, 2024 |
| FY2023 | Mar 31, 2021 | $84.0K | Jun 27, 2023 |
| FY2022 | Mar 31, 2020 | $1.05M | Jun 22, 2022 |
| FY2021 | Mar 31, 2019 | ($3.00M) | Jun 22, 2021 |
| FY2020 | Mar 31, 2018 | $1.41M | Jun 23, 2020 |
| FY2018 | Mar 31, 2017 | ($682.0K) | Jul 1, 2019 |
| FY2018 | Mar 31, 2016 | ($785.0K) | Jun 21, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $449.0K | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | $689.0K | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | $770.0K | Jun 26, 2024 |
| FY2024 | Mar 31, 2022 | $712.0K | Jun 26, 2024 |
| FY2023 | Mar 31, 2021 | $639.0K | Jun 27, 2023 |
| FY2022 | Mar 31, 2020 | $608.0K | Jun 22, 2022 |
| FY2021 | Mar 31, 2019 | $923.0K | Jun 22, 2021 |
| FY2020 | Mar 31, 2018 | $563.0K | Jun 23, 2020 |
| FY2018 | Mar 31, 2017 | $593.0K | Jul 1, 2019 |
| FY2018 | Mar 31, 2016 | $633.0K | Jun 21, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($1.19M) | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | ($455.0K) | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | ($2.10M) | Jun 26, 2024 |
| FY2024 | Mar 31, 2022 | $2.38M | Jun 26, 2024 |
| FY2023 | Mar 31, 2021 | $2.40M | Jun 27, 2023 |
| FY2022 | Mar 31, 2020 | $1.24M | Jun 22, 2022 |
| FY2021 | Mar 31, 2019 | ($847.0K) | Jun 22, 2021 |
| FY2020 | Mar 31, 2018 | $1.49M | Jun 23, 2020 |
| FY2018 | Mar 31, 2017 | $1.22M | Jul 1, 2019 |
| FY2018 | Mar 31, 2016 | $745.0K | Jun 21, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $23.49M | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | $25.11M | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | $29.73M | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | $32.05M | Jun 27, 2023 |
| FY2022 | Mar 31, 2021 | $30.88M | Jun 22, 2022 |
| FY2021 | Mar 31, 2020 | $31.79M | Jun 22, 2021 |
| FY2020 | Mar 31, 2019 | $29.63M | Jun 23, 2020 |
| FY2018 | Mar 31, 2018 | $29.71M | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | $29.16M | Jun 21, 2018 |
| FY2017 | Mar 31, 2016 | $31.15M | Jun 22, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $14.61M | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | $13.30M | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | $13.38M | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | $12.56M | Jun 27, 2023 |
| FY2022 | Mar 31, 2021 | $13.84M | Jun 22, 2022 |
| FY2021 | Mar 31, 2020 | $15.94M | Jun 22, 2021 |
| FY2020 | Mar 31, 2019 | $14.72M | Jun 23, 2020 |
| FY2018 | Mar 31, 2018 | $11.60M | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | $12.55M | Jun 21, 2018 |
| FY2017 | Mar 31, 2016 | $13.32M | Jun 22, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $8.88M | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | $11.81M | Jun 20, 2025 |
| FY2025 | Mar 31, 2023 | $16.35M | Jun 20, 2025 |
| FY2024 | Mar 31, 2022 | $19.49M | Jun 26, 2024 |
| FY2024 | Mar 31, 2021 | $17.04M | Jun 26, 2024 |
| FY2023 | Mar 31, 2020 | $15.85M | Jun 27, 2023 |
| FY2022 | Mar 31, 2019 | $14.91M | Jun 22, 2022 |
| FY2021 | Mar 31, 2018 | $18.11M | Jun 22, 2021 |
| FY2020 | Mar 31, 2017 | $16.61M | Jun 23, 2020 |
| FY2018 | Mar 31, 2016 | $17.83M | Jul 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($26.10M) | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | ($22.90M) | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | ($17.63M) | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | ($14.19M) | Jun 27, 2023 |
| FY2022 | Mar 31, 2021 | ($16.35M) | Jun 22, 2022 |
| FY2021 | Mar 31, 2020 | ($17.27M) | Jun 22, 2021 |
| FY2020 | Mar 31, 2019 | ($17.66M) | Jun 23, 2020 |
| FY2018 | Mar 31, 2018 | ($14.06M) | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | ($15.08M) | Jun 21, 2018 |
| FY2017 | Mar 31, 2016 | ($13.87M) | Jun 22, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $257.0K | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | $707.0K | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | $974.0K | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | $2.59M | Jun 27, 2023 |
| FY2022 | Mar 31, 2021 | $3.77M | Jun 22, 2022 |
| FY2021 | Mar 31, 2020 | $2.42M | Jun 22, 2021 |
| FY2020 | Mar 31, 2019 | $840.0K | Jun 23, 2020 |
| FY2020 | Mar 31, 2018 | $1.33M | Jun 23, 2020 |
| FY2018 | Mar 31, 2017 | $1.41M | Jul 1, 2019 |
| FY2018 | Mar 31, 2016 | $1.24M | Jun 21, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $4.71M | Jun 20, 2025 |
| FY2024 | Mar 31, 2024 | $5.46M | Jun 26, 2024 |
| FY2023 | Mar 31, 2023 | $4.46M | Jun 27, 2023 |
| FY2022 | Mar 31, 2022 | $4.94M | Jun 22, 2022 |
| FY2021 | Mar 31, 2021 | $6.17M | Jun 22, 2021 |
| FY2020 | Mar 31, 2020 | $6.87M | Jun 23, 2020 |
| FY2018 | Mar 31, 2019 | $126.0K | Jul 1, 2019 |
| FY2018 | Mar 31, 2018 | $156.0K | Jul 1, 2019 |
| FY2012 | Mar 31, 2013 | $5.45M | Jun 24, 2013 |
| FY2012 | Mar 31, 2012 | $400.0K | Jun 24, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Jun 26, 2024 |
| FY2024 | Mar 31, 2022 | 0 | Jun 26, 2024 |
| FY2023 | Mar 31, 2021 | 0 | Jun 27, 2023 |
| FY2022 | Mar 31, 2020 | 0 | Jun 22, 2022 |
| FY2021 | Mar 31, 2019 | 0 | Jun 22, 2021 |
| FY2020 | Mar 31, 2018 | 0 | Jun 23, 2020 |
| FY2018 | Mar 31, 2017 | 0 | Jul 1, 2019 |
| FY2018 | Mar 31, 2016 | 0 | Jun 21, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Mar 31, 2024 | 0 | Jun 26, 2024 |
| FY2024 | Mar 31, 2023 | 0 | Jun 26, 2024 |
| FY2024 | Mar 31, 2022 | 0 | Jun 26, 2024 |
| FY2023 | Mar 31, 2021 | 0 | Jun 27, 2023 |
| FY2022 | Mar 31, 2020 | 0 | Jun 22, 2022 |
| FY2021 | Mar 31, 2019 | 0 | Jun 22, 2021 |
| FY2020 | Mar 31, 2018 | 0 | Jun 23, 2020 |
| FY2018 | Mar 31, 2017 | 0 | Jul 1, 2019 |
| FY2018 | Mar 31, 2016 | 0 | Jun 21, 2018 |
| FY2015 | Mar 31, 2015 | 0 | Jul 15, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 7.20M | Jun 20, 2025 |
| FY2025 | Mar 31, 2024 | 6.95M | Jun 20, 2025 |
| FY2024 | Mar 31, 2023 | 6.27M | Jun 26, 2024 |
| FY2023 | Mar 31, 2022 | 6.20M | Jun 27, 2023 |
| FY2022 | Mar 31, 2021 | 6.12M | Jun 22, 2022 |
| FY2021 | Mar 31, 2020 | 6.01M | Jun 22, 2021 |
| FY2020 | Mar 31, 2019 | 5.88M | Jun 23, 2020 |
| FY2018 | Mar 31, 2018 | 5.77M | Jul 1, 2019 |
| FY2018 | Mar 31, 2017 | 5.69M | Jun 21, 2018 |
| FY2017 | Mar 31, 2016 | 5.60M | Jun 22, 2017 |